



<https://providers.amerigroup.com>

## Buprenorphine/Naloxone Prior Authorization of Benefits Form

**CONTAINS CONFIDENTIAL PATIENT INFORMATION**

**Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004.**

**Provider Help Desk: 1-800-454-3730**

<b>1. Patient information</b>		<b>2. Physician information</b>	
Patient name: _____		Prescribing physician: _____	
Patient ID #: _____		Physician address: _____	
Patient DOB: _____		Physician phone #: _____	
Date of Rx: _____		Physician fax #: _____	
Patient phone #: _____		Physician specialty: _____	
Patient email address: _____		Physician DEA: _____	
		Physician NPI #: _____	
		Physician email address: _____	
<b>3. Medication</b>	<b>4. Strength</b>	<b>5. Directions</b>	<b>6. Quantity per 30 days</b>
_____	_____	_____	Specify: _____
<b>7. Diagnosis:</b> _____			
<b>8. Approval criteria:</b> (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)			
<p>Prior authorization (PA) is required for transmucosal buprenorphine or buprenorphine/naloxone. Requests will be considered for FDA approved dosing, including induction and maintenance dose. Requests for doses above 24 mg per day will not be considered. Initial requests will be considered for up to three months. Requests for maintenance doses above 16 mg per day will not be considered on a long-term basis. After the initial three month PA, renewal requests for doses ≤ 16mg per day may be considered for 12-month renewals as long as the member meets all other PA criteria. Payment for a non-preferred agent will be authorized only for cases in which there is documentation of previous trial and therapy failure with a preferred agent, unless evidence is provided that use of these agents would be medically contraindicated. Requests for surgically implanted buprenorphine or buprenorphine depot injections products will not be considered through the pharmacy benefit and should be directed to the member’s medical benefit. Payment will be considered when the following is met:</p> <ol style="list-style-type: none"> <li>1. Patient has a diagnosis of opioid dependence and meets the FDA-approved age</li> <li>2. Prescriber meets qualification criteria to prescribe buprenorphine/naloxone for opioid dependence and has an “X” DEA number (provide X DEA number)</li> <li>3. Documentation the Iowa Prescription Monitoring Program website has been reviewed for the patient’s use of controlled substances</li> <li>4. Documentation is provided that transmucosal buprenorphine will not be used concomitantly with the buprenorphine implant or depot injection</li> <li>5. Requests for single ingredient buprenorphine will only be considered for pregnant patients</li> </ol>			

